A Case of Anti-Synthetase Syndrome Successfully Treated with Mycophenolate Mofetil and Rituximab but No Corticosteroids
  • Agnieszka Ewa Sieradzka
    Private Practice, Riva San Vitale, Ticino, Switzerland
  • Bruno Naccini
    Pneumology Service, Ospedale Beata Vergine, Mendrisio, Ticino, Switzerland
  • Massimiliano Fontana
    Allergology and Clinical Immunology Service, Ospedale Beata Vergine, Mendrisio, Ticino, Switzerland

Keywords

Antisynthetase syndrome, interstitial lung disease, polymyositis/dermatomyositis, idiopathic inflammatory myopathy, mycophenolate mofetil, Rituximab, corticosteroids.

Abstract

A patient with antisynthetase syndrome with pulmonary and muscular involvement was treated with immunosuppressive agents without corticosteroids. Rituximab was added to mycophenolate mofetil therapy with improvement in lung functional and imaging findings and normalization of creatine kinase levels.

VIEW THE ENTIRE ARTICLE

References

  • Barba T, Fort R, Cottin V, Provencher S, Dureu I, Jardel S, et al. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis. Autoimmun Rev 2019;18(2):113–122.
  • Witt LJ, Curran JJ, Strek ME. The diagnosis and treatment of antisynthetase syndrome. Clin Pulm Med 2016;23(5):218–226.
  • Marco JL, Collins BF. Clinical manifestations and treatment of antisynthetase syndrome. Best Pract Res Clin Rheumatol 2020;34(4):101503.
  • Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine and methotrexate and a comparison of their efficacy. Am J Med 1993;94:379–387.
  • Labirua-Iturburu A, Selva-O'Callaghan A, Martínez-Gomez X, Trallero-Araguas E, Labrador-Horrillo M, Vilardell-Tarres M. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rheumatol 2013;31(3):436–439.
  • Andersson H, Sem M, Lund MB, Aaløkken TM, Günther A, Walle-Hansen R, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford) 2015;54(8):1420–1428.
  • Bauhammer J, Blank N, Max R, Lorenz H-M, Wagner U, Krause D, et al. Rituximab in the treatment of Jo1 antibody associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response. J Rheumatol 2016;43(8):1566–1574.
  • Marie I, Dominique S, Janvresse A, Levesque H, Menard JF. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Resp Med 2012;106:581–587.
  • Doyle TJ, Dhillon N, Madan R, Cabral F, Fletcher EA, Koontz DC, et al. Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multi-center retrospective case review. J Rheumatol 2018;45(6):841–850.

    • Views: 738
    HTML downloads: 131
    PDF downloads: 337

    Published: 2022-07-18
    Issue: 2022: Vol 9 No 7 (view)

    How to cite:
    1.
    Sieradzka AE, Naccini B, Fontana M. A Case of Anti-Synthetase Syndrome Successfully Treated with Mycophenolate Mofetil and Rituximab but No Corticosteroids. EJCRIM 2022;9 doi:10.12890/2022_003324.